Hero product image: Official Lilly Mounjaro 5 mg single-dose prefilled pen.[4] Other strengths use different label colors.
The FDA has approved Mounjaro (tirzepatide) to lower the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with type 2 diabetes who are at high risk for these events. Eli Lilly announced the expanded indication on August 28, 2026.[1]
This is an additional use for Mounjaro. The drug was already approved, along with diet and exercise, to improve blood sugar in adults and children age 10 and older with type 2 diabetes. The new cardiovascular indication is for adults.[1]
The approval came from SURPASS-CVOT, a large trial that compared Mounjaro with Trulicity (dulaglutide). Trulicity was a demanding comparator because it already had evidence of cardiovascular benefit. The trial found that Mounjaro was noninferior to Trulicity. It did not establish that Mounjaro was superior.[1][2]
What the FDA approved
The new indication covers three major adverse cardiovascular events, often grouped as MACE-3:
- Death from cardiovascular causes
- Nonfatal myocardial infarction, commonly called a heart attack
- Nonfatal stroke
It applies to adults who have type 2 diabetes and are at high risk for these events.[1]
The announcement does not say that Mounjaro prevents every heart attack or stroke. It also does not replace statins, blood-pressure treatment, antiplatelet therapy, or other care a clinician has prescribed for cardiovascular risk.
The SURPASS-CVOT results
SURPASS-CVOT was a randomized, double-blind Phase 3 trial in people with type 2 diabetes and established atherosclerotic cardiovascular disease. A total of 13,299 people were randomized, and the modified intention-to-treat analysis included 13,165 participants after 134 people were excluded for not meeting entry criteria.[1][2]
Participants received once-weekly tirzepatide, up to 15 mg or their maximum tolerated dose, or dulaglutide 1.5 mg. Median follow-up was 210.1 weeks, about four years.[1]
The primary MACE-3 outcome occurred in:
- 12.2% of the tirzepatide group
- 13.1% of the dulaglutide group
The hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01. Tirzepatide met the trial's standard for noninferiority (P=0.003) but not superiority (P=0.09).[2]
What the "8% lower" number means
Lilly describes the result as an 8% lower rate of cardiovascular death, heart attack, or stroke compared with Trulicity. That figure comes from the hazard ratio of 0.92.[1][2]
It does not mean cardiovascular events fell by 8 percentage points. The observed event rates differed by 0.9 percentage points: 12.2% with tirzepatide versus 13.1% with dulaglutide.[2]
It also was not an 8% reduction versus placebo or no treatment. Mounjaro was tested against Trulicity, a GLP-1 medication with established cardiovascular benefit. This active-comparator design helps answer whether tirzepatide performs at least as well as an effective option, but it makes the headline harder to summarize accurately.
The clean reading is that Mounjaro preserved cardiovascular protection compared with Trulicity while meeting the study's noninferiority standard. The study did not prove that Mounjaro was better than Trulicity at preventing MACE-3.[1][2]
Noninferior does not mean ineffective
A noninferiority trial asks whether a new treatment avoids being unacceptably worse than an established treatment. SURPASS-CVOT was not designed around a placebo comparison. Researchers compared tirzepatide with dulaglutide because dulaglutide already had cardiovascular-outcome evidence.[1][2]
The confidence interval is important. It ranged from 0.83 to 1.01. Because the upper end slightly crossed 1.00, the trial could not establish statistical superiority for tirzepatide over dulaglutide.[2]
That is why the following statements would overreach:
- Mounjaro is better than Trulicity for preventing heart attacks
- Mounjaro cuts cardiovascular risk by eight percentage points
- Everyone taking tirzepatide receives the same heart protection
The FDA indication is meaningful, but it has a defined population and a specific evidence base.
Who was studied versus who received the indication
The trial enrolled adults with type 2 diabetes and established atherosclerotic cardiovascular disease. That includes disease affecting the coronary, cerebral, or peripheral arteries.[1][2]
The approved wording reported by Lilly is broader in phrasing: adults with type 2 diabetes who are at high risk for cardiovascular events.[1]
A prescriber decides whether a patient's medical history fits the approved indication. A person should not assume that one risk factor, or simply taking Mounjaro, means the cardiovascular indication applies to them.
The approval does not extend to Zepbound
Mounjaro and Zepbound contain the same active drug, tirzepatide, but they have different brand-specific FDA indications. Mounjaro is the diabetes brand. Zepbound is approved for chronic weight management and certain other obesity-related uses.
The August 28 announcement adds the cardiovascular claim to Mounjaro for adults with type 2 diabetes at high cardiovascular risk. It does not announce the same indication for Zepbound.[1]
This distinction matters for patients, clinicians, insurance coverage, and advertising. Evidence about the tirzepatide molecule does not automatically rewrite both brands' approved labels.
For the differences between the two brands, read our Mounjaro vs. Zepbound guide and our broader tirzepatide guide.
The approval does not change dosing instructions
The approval adds a cardiovascular use; it is not an instruction for patients to increase their dose.
SURPASS-CVOT used tirzepatide up to 15 mg or the maximum tolerated dose, compared with dulaglutide 1.5 mg.[1] That describes the research protocol. A prescriber determines an individual's dose based on the current FDA label, blood-sugar response, tolerability, other medications, and medical history.
Do not change a Mounjaro dose to pursue cardiovascular benefit without speaking with the prescribing clinician.
Safety findings and existing warnings
Lilly reported that Mounjaro's safety and tolerability in SURPASS-CVOT were generally consistent with its established profile. Gastrointestinal problems were the most commonly reported adverse events, were generally mild to moderate, and occurred mainly during dose escalation.[1]
The current prescribing information lists nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain among the most common adverse reactions.[3]
Mounjaro retains a boxed warning about thyroid C-cell tumors observed in rats. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.[3]
Other serious warnings and precautions include pancreatitis, hypoglycemia when used with insulin or certain diabetes drugs, serious allergic reactions, kidney injury related to dehydration, severe gastrointestinal reactions, gallbladder disease, and possible pulmonary aspiration during anesthesia or deep sedation.[3]
This is not a complete safety list. Patients should use the medication exactly as prescribed and review the latest Medication Guide and prescribing information.
How this compares with other GLP-1 heart indications
Mounjaro now joins diabetes medications such as Ozempic (semaglutide), Trulicity, and Victoza (liraglutide) with cardiovascular-outcome evidence and an approved cardiovascular-risk indication in defined populations.
The studies are not interchangeable. They used different comparators, eligibility rules, follow-up periods, and statistical plans. A percentage from a placebo-controlled trial cannot be compared directly with Mounjaro's 8% relative hazard difference versus an active drug.
Wegovy (semaglutide) also has a cardiovascular indication for adults with established cardiovascular disease and obesity or overweight, including people without diabetes. That is a different labeled population from Mounjaro's new indication.
Our GLP-1 heart-health guide explains the major cardiovascular trials and their different patient populations.
What patients can ask their prescriber
People with type 2 diabetes and heart disease or multiple cardiovascular risk factors may want to ask:
- Does my history fit Mounjaro's new cardiovascular indication?
- How does Mounjaro compare with my current diabetes medication for my specific risks?
- Should my statin, blood-pressure medication, or other heart treatment stay the same?
- What side effects or blood-sugar changes should I monitor?
- Will the new indication affect insurance coverage for me?
The approval adds evidence for a specific use. It does not make Mounjaro the right medication for every person with type 2 diabetes.
Bottom line
The FDA has approved Mounjaro to lower the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with type 2 diabetes who are at high risk.[1]
SURPASS-CVOT showed that tirzepatide was noninferior to Trulicity for MACE-3. Event rates were 12.2% and 13.1%, respectively, and superiority over Trulicity was not established.[1][2]
The approval gives Mounjaro a cardiovascular indication backed by a long, active-comparator trial. The accurate takeaway is not that Mounjaro beat Trulicity. It is that Mounjaro met the standard for cardiovascular protection against a medication that already had proven benefit.
This article provides general information and does not replace advice from a clinician who knows your medical history.
